Rapid risk assessment – Carbapenem-resistant Enterobacterales – third update

The European Commission’s rapid risk assessment on carbapenem-resistant Enterobacterales (CRE) in the EU/EEA has shown a deteriorating epidemiological situation, with an increase in CRE bloodstream infections in 23 EU Member States. The probability of further spread is high due to high mortality rates and limited treatment options. To control CRE, enhanced efforts are needed, including national coordination, developing a CRE management plan, implementing enhanced infection prevention and control measures, applying antimicrobial stewardship, strengthening genomic surveillance, providing laboratory capacity for rapid detection and characterization, and strengthening innovation and access to antimicrobials.